Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C
 and on the inhibition of CETP activity versus placebo, in patients presenting with mild
 dyslipidaemia. These objectives will be tested after 4 weeks of treatment.
Inclusion Criteria:

 -  Patients with of Type II hyperlipidaemia

 -  Patients having lipid values as indicated below:

 -  HDL-C < 1.6 mmol/l

 -  TG < 4.5 mmol/l

 -  Male and females between 18 and 65 years old (If female must be post-menopausal, or
 pre-menopausal and surgically sterile or using an acceptable form of contraception)

 Exclusion Criteria:

 -  Body Mass Index (BMI) > 35 kg/m²

 -  Pregnant, breast feeding, or woman with child bearing potential without an effective
 method of contraception

 -  Concomitant use of medications identified in the protocol